Informa
08:00 - 08:40

Registration and Coffee

More
Showing of Streams
12:20 - 13:40
Info

Luncheon Provided for Full-Day Workshop Attendees

Luncheon Provided for Full-Day Workshop Attendees Only (Those registered for both workshop A and workshop B)

More
Showing of Streams
08:00 - 08:40 40 mins
Registration and Coffee
08:40 - 08:45 5 mins
Workshop A: Bispecific Antibodies: New Strategies and Case Studies
Workshop Moderator’s Remarks
  • Aran Labrijn, PhD - Principal Scientist, Antibody Research and Technology, Genmab
08:45 - 09:15 30 mins
Info
Workshop A: Bispecific Antibodies: New Strategies and Case Studies
Bispecific Antibodies: History and (Future) Promises
  • Aran Labrijn, PhD - Principal Scientist, Antibody Research and Technology, Genmab

Since the concept of a man-made bispecific antibody was originally described (almost 60 years ago), many technical and conceptual advances have led to the extensive bispecific antibody landscape known today. A short historical perspective will be given, including discussion of the different bispecific antibody classes, the unique opportunities for dual-targeting and the (current) challenges facing the (pre-)clinical development of bispecific antibodies.

09:15 - 09:45 30 mins
Info
Workshop A: Bispecific Antibodies: New Strategies and Case Studies
Bispecific Target Discovery by High Throughput Functional Screening of Hundreds of Combinations of Different Target Pairs
  • Laura Starkie, PhD - Principal Scientist, Bispecific Target Discovery, UCB


To exploit the true potential to access novel biology with bispecific antibodies we have developed technology to facilitate unbiased target pair identification and validation through grid screening in functional human cell assays large numbers of bispecific antibodies. Combination of our antibody discovery capabilities, a novel bispecific screening format and high throughput flow cytometry or imaging enables us to screen thousands of bispecific antibodies to hundreds of antigen combinations and identify new target pairs for a defined patient phenotype. The technology and a specific example application from patient phenotyping to new target pair discovery will be described.


09:45 - 10:15 30 mins
Info
Workshop A: Bispecific Antibodies: New Strategies and Case Studies
The Use of Unbiased Screens to Identify Bispecific Antibodies with a Unique Mode of Action
  • Cecile Geuijen, PhD - Vice President, Oncology, Merus


Target-based drug discovery based on disease modelling and pathway analysis mainly focusses on a design approach for bispecific antibodies. Our strategy uses an unbiased approach with a functional readout that allows the discovery of bispecific antibodies with unique features and biology. The process of functional screening to lead bispecific antibody of several of our clinical candidates will be described in this presentation.

10:15 - 10:45 30 mins
Workshop A: Bispecific Antibodies: New Strategies and Case Studies
Networking Refreshment Break
10:45 - 11:15 30 mins
Info
Workshop A: Bispecific Antibodies: New Strategies and Case Studies
The Immunology Underlying CD3-bispecific Antibody Treatment
  • Thorbald Van Hall, PhD - Associate Professor, Leiden University Medical Center

Immunotherapy of cancer with CD3-targeting bispecific antibodies (CD3 bsAb) is a very promising strategy, also for solid malignancies. Xenograft mouse models often fail to fully recapitulate the natural tumor microenvironment, and therefore we investigated the immunological consequences of CD3 bsAb therapy in fully immune-competent mouse tumor models.

11:15 - 11:45 30 mins
Info
Workshop A: Bispecific Antibodies: New Strategies and Case Studies
Dual Targeting Approach Using Complementary Hemi-Bodies
  • Gernot Stuhler, MD - Immunotherapy Lab, University Hospital Wurzburg

Antigens suitable for T cell redirecting strategies against cancer are scarce. Consequently, we developed an antibody derivative, which comes in two complementary halves and addresses antigen combinations instead of single molecules. Each half contains an antigen specific scFv fused to either the VL or VH domain of an anti-CD3 antibody. When these two hemibodies bind their respective antigens on a cancer cell, they reconstitute “on target” the original CD3-binding site to engage T lymphocytes.

11:45 - 12:15 30 mins
Workshop A: Bispecific Antibodies: New Strategies and Case Studies
J-chain Based Bispecifics: IgM CD20xCD3
  • Bruce Keyt, Ph.D. - Chief Scientific Officer, IGM Biosciences Inc
12:15 - 12:20 5 mins
Workshop A: Bispecific Antibodies: New Strategies and Case Studies
Close of Workshop A
12:20 - 13:40 80 mins
Info
Luncheon Provided for Full-Day Workshop Attendees

Luncheon Provided for Full-Day Workshop Attendees Only (Those registered for both workshop A and workshop B)

13:40 - 13:45 5 mins
Workshop B: ADCs: New Strategies and Case Studies
Workshop Moderator’s Remarks
  • Esther Breij, PhD - Associate Director, Genmab BV
13:45 - 14:15 30 mins
Info
Workshop B: ADCs: New Strategies and Case Studies
Insights into Conjugation Processes Employed in the Development of Therapeutic ADCs
  • Justyna Mysliwy, PhD - Bioconjugation Team Leader, Iksuda Therapeutics Ltd

Conjugation strategies are of great importance in the successful design and development of effective ADCs. The impact of current conjugation technologies on ADC stability, therapeutic index and pharmacokinetics will be discussed. Additionally, challenges and advancements in techniques for chemical modification of antibodies will be explored.

14:15 - 14:45 30 mins
Info
Workshop B: ADCs: New Strategies and Case Studies
Challenges in Process Development of Antibody-drug Conjugates (ADCs)
  • Guy De Roo, PhD - Principle Scientist, Synthon Biopharmaceuticals BV

Synthon's ADC technology aims to create ADCs having an optimal therapeutic window, balancing the effect of potent cell-killing agents on tumor cells versus healthy cells. Case studies will be presented of various ADCs in development together with challenges which are observed during conjugation, purification and manufacturing.

14:45 - 15:15 30 mins
Info
Workshop B: ADCs: New Strategies and Case Studies
The Pyrrolobenzodiazepine (PBD) Dimer Class of ADC Warhead
  • John Hartley, PhD - Professor of Cancer Studies, UCL and Director of Pre-clinical Development, Spirogen Ltd, University College London


The rationally designed PBD dimers have emerged as an important class of ADC warhead which exert their activity through forming highly cytotoxic DNA interstrand cross-links in the DNA minor groove. This presentation will describe how an understanding of structure activity relationships has enabled this flexible platform to be tailored to individual requirements in novel ADCs.

15:15 - 15:45 30 mins
Workshop B: ADCs: New Strategies and Case Studies
Networking Refreshment Break
15:45 - 16:15 30 mins
Info
Workshop B: ADCs: New Strategies and Case Studies
Preclinical Development of Enapotamab Vedotin - Opportunities in Treatment Resistant Solid Cancers
  • Esther Breij, PhD - Associate Director, Genmab BV

The presentation will provide an overview of the preclinical anti-tumor activity of enapotamab vedotin in (treatment-resistant) preclinical models for melanoma and NSCLC.

16:15 - 16:45 30 mins
Info
Workshop B: ADCs: New Strategies and Case Studies
Development of Highly Potent Pyrrolobenzodiazepine Based ADCs from Bench to Clinic: Challenges and Lessons Learned
  • Patrick Van Berkel, PhD - Senior Vice President Research and Development, ADC Therapeutics (UK) Limited

Pyrrolobenzodiazepine (PBD) dimers represent a promising new class of toxins for the development of antibody drug conjugates (ADCs). More than a dozen PBD-based ADCs are currently in various stages of clinical development for the treatment of various malignancies. This presentation will highlight some experiences when developing PBD-based ADCs from bench to clinic.

16:45 - 17:15 30 mins
Info
Workshop B: ADCs: New Strategies and Case Studies
ADC Technologies, Strategies to Improve Therapeutic Index and Efficacy
  • Juhani Saarinen - Chief Executive Officer, Glykos Finland Oy

Today’s ADCs utilize different antigen targets, conjugation technologies, and payload warheads of various mechanisms such as tubulin inhibitors, DNA damaging, topoisomerase inhibition, or DNA polymerase II inhibitors. The main challenge remains to reach desirable efficacious doses due to the toxicity profile. Advanced methods to improve therapeutic index, including increasing ADC hydrophilicity, are presented.


17:15 - 17:20 5 mins
Workshop B: ADCs: New Strategies and Case Studies
Close of Workshop B

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。